BioMed Research International

Research Article

Controlling Nutritional Status (CONUT) as a Novel Postoperative Prognostic Marker in Breast Cancer Patients: A Retrospective Study

Table 5

Univariate and multivariate Cox regression survival analyses of the CONUT score for the prediction of DFS and OS in BC patients.


Parameters	DFS				OS
	Univariate analysis	value	Multivariate analysis	value	Univariate analysis	value	Multivariate analysis	value
	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value

Cases ()
Age (years)		0.183				0.646
< 50	1 (reference)				1 (reference)
≥ 50	1.502(0.825-2.733)				1.195(0.558-2.558)
BMI		0.595				0.778
< 24.45	1 (reference)				1 (reference)
≥ 24.45	1.281(0.514-3.196)				0.899(0.428-1.888)
Family history		0.229				0.857
No	1 (reference)				1 (reference)
Yes	0.694(0.383-1.258)				0.952(0.555-1.633)
Menopause		0.312				0.943
No	1 (reference)				1 (reference)
Yes	0.660(0.295-1.477)				1.027(0.494-2.134)
Type of surgery		0.608				0.931
Mastectomy	1 (reference)				1 (reference)
Breast-conserving surgery	0.685(0.162-2.908)				0.959(0.376-2.450)
Tumor size		0.061				0.918
≤2 cm	1 (reference)				1 (reference)
> 2 and< 5 cm	2.093(1.134-3.863)	0.018			1.093(0.665-1.798)	0.726
≥ 5 cm	1.424(0.639-3.173)	0.388			1.133(0.524-2.450)	0.752
Postoperative chemotherapy		<0.0001		<0.0001		<0.0001		<0.0001
No	1 (reference)		1 (reference)		1 (reference)		1 (reference)
Yes	3.865(1.935-7.722)		4.104(2.312-7.285)		3.256(1.937-5.473)		3.594(1.953-6.613)
Postoperative radiotherapy		<0.0001		<0.0001		0.009		0.010
No	1 (reference)		1 (reference)		1 (reference)		1 (reference)
Yes	0.217(0.102-0.461)		0.348(0.196-0.618)		0.474(0.271-0.828)		0.451(0.246-0.828)
Postoperative endocrine therapy		0.204				0.693
No	1 (reference)				1 (reference)
Yes	0.637(0.318-1.276)				0.878(0.460-1.676)
Postoperative targeted therapy		0.301				0.884
No	1 (reference)				1 (reference)
Yes	1.560(0.672-3.622)				0.946(0.450-1.990)
ALB (g/L)		0.984				0.922
< 44.10	1 (reference)				1 (reference)
≥ 44.10	1.007(0.509-1.990)				0.969(0.512-1.832)
Total serum cholesterol (TC) (mmol/L)		0.015		0.012		0.021		0.002
< 4.38	1 (reference)		1 (reference)		1 (reference)		1 (reference)
≥ 4.38	0.488(0.274-0.871)		0.591(0.392-0.893)		0.638(0.436-0.933)		0.484(0.308-0.760)
TP(g/L)		0.274				1.000
< 71.90	1 (reference)				1 (reference)
≥ 71.90	0.712(0.388-1.308)				1.000(0.600-1.666)
PALB(mg/dl)		0.055				0.745
< 24	1 (reference)				1 (reference)
≥ 24	0.577(0.329-1.012)				0.921(0.562-1.510)
White blood cell (W) (×10⁹/L)		0.360				0.875
< 5.92	1 (reference)				1 (reference)
≥ 5.92	1.483(0.638-3.446)				1.060(0.517-2.173)
Neutrophil (N) (×10⁹/L)		0.195				0.937
< 3.41	1 (reference)				1 (reference)
≥ 3.41	0.582(0.257-1.319)				0.971(0.467-2.016)
Total lymphocyte (TLC) (×10⁹/L)		0.670				0.739
< 1.87	1 (reference)				1 (reference)
≥ 1.87	1.192(0.531-2.675)				1.122(0.570-2.209)
Monocyte (M) (×10⁹/L)		0.399				0.910
< 0.34	1 (reference)				1 (reference)
≥ 0.34	1.402(0.639-3.075)				0.963(0.503-1.844)
Platelet (P) (×10⁹/L)		0.315				0.706
< 235	1 (reference)				1 (reference)
≥ 235	1.379(0.736-2.582)				0.901(0.522-1.553)
CONUT		<0.0001		<0.0001		<0.0001		<0.0001
< 1	1 (reference)		1 (reference)		1 (reference)		1 (reference)
≥ 1	3.184(1.786-5.677)		2.465(1.642-3.700)		2.326(1.578-3.429)		2.775(1.791-4.300)
Molecular subtype		0.145				0.955
Luminal A	1 (reference)				1 (reference)
Luminal B HER2+	0.419(0.098-1.795)	0.241			0.668(0.122-3.648)	0.641
Luminal B HER2-	1.650(0.801-3.400)	0.175			1.092(0.459-2.598)	0.843
HER2 enriched	0.314(0.066-1.484)	0.144			0.809(0.144-4.547)	0.810
Triple negative	1.076(0.374-3.094)	0.892			1.424(0.393-5.166)	0.591
ER status		0.130				0.073
0-25%	1 (reference)				1 (reference)
26-50%	1.260(0.561-2.828)	0.575			1.690(0.740-3.858)	0.213
51-75%	1.507(0.574-3.956)	0.405			3.353(1.347-8.344)	0.009
76-100%	0.703(0.345-1.432)	0.332)			1.594(0.768-3.307)	0.211
PR status		0.458				0.995
0-25%	1 (reference)				1 (reference)
26-50%	0.761(0.344-1.683)	0.501			1.104(0.518-2.356)	0.798
51-75%	2.332(0.602-9.030)	0.220			1.028(0.364-2.907)	0.958
76-100%	0.858(0.374-1.970)	0.719			1.060(0.522-2.154)	0.872
HER2 status		0.089				0.443
Negative (0--++)	1 (reference)				1 (reference)
Positive (+++)	2.842(0.853-9.473)				1.803(0.401-8.110)
Ki-67 status		0.059				0.966
0-25%	1 (reference)				1 (reference)
26-50%	1.132(0.552-2.319)	0.736			0.967(0.516-1.811)	0.915
51-75%	2.755(1.026-7.396)	0.044			1.090(0.469-2.535)	0.841
76-100%	0.124(0.008-1.973)	0.139			0.751(0.190-2.964)	0.682
AR status		0.927				0.983
0-25%	1 (reference)				1 (reference)
26-50%	3.019(0.467-19.517)	0.981			0.862(0.036-20.773)	0.927
51-75%	0.000(0.000-6.410)	0.975			1.048(0.089-12.333)	0.970
76-100%	2.123(0.240-18.756)	0.498			1.519(0.181-12.737)	0.700
P53 status		0.655				0.934
0-25%	1 (reference)				1 (reference)
26-50%	1.471(0.757-2.859)	0.255			0.883(0.373-2.093)	0.778
51-75%	0.902(0.510-1.598)	0.725			1.073(0.553-2.080)	0.836
76-100%	0.812(0.147-4.477)	0.811			1.669(0.267-10.420)	0.583
CK5/6 status		0.711				0.702
Negative	1 (reference)				1 (reference)
Positive	1.169(0.513-2.664)				1.237(0.415-3.686)
E-cad status		0.597				0.900
Negative	1 (reference)				1 (reference)
Positive	1.219(0.585-2.542)				1.038(0.579-1.859)
EGFR status		0.487				0.875
Negative	1 (reference)				1 (reference)
Positive	0.686(0.238-1.983)				0.936(0.411-2.133)
Lymph vessel invasion		0.001		0.037		0.937
Negative	1 (reference)		1 (reference)		1 (reference)
Positive	2.691(1.469-4.930)		1.560(1.028-2.368)		1.021(0.610-1.708)
Neural invasion		0.119				0.874
Negative	1 (reference)				1 (reference)
Positive	0.489(0.199-1.201)				0.941(0.447-1.983)